This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Industry Outlook - October 2017
by Arpita Dutt
New product sales ramping up, R&D success and innovation, strong results, a higher number of FDA approvals and continued strong performance from key products are some of the factors that could contribute to a sustained recovery in the sector.
Spin-Off ETF: Can the Outperformance Continue?
by Sanghamitra Saha
Spin-off activities picked up pace in the United States.
Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback
by Arpita Dutt
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.
Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib
by Zacks Equity Research
Merck (MRK) is not seeking approval for its CETP inhibitor anacetrapib, which it had developed for cholesterol management.
Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study
by Zacks Equity Research
Lilly's breast cancer drug, Verzenio, failed to achieve primary endpoint in a phase III study evaluating the drug as monotherapy in advanced lung cancer patients.
Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit
by Zacks Equity Research
Pfizer (PFE) is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin-off, sale or other transaction.
Stock Market News For Oct 11, 2017
by Zacks Equity Research
The Dow notched up another record close on Tuesday, following a surge in shares of Wal-Mart.
5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
by Arpita Dutt
Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.
AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
by Zacks Equity Research
AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.
Forget Teva (TEVA), Buy These 5 Drug Stocks Instead
by Arpita Dutt
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.
4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3
by Zacks Equity Research
The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.
Allergan's Botox Gets FDA Nod for Forehead Line Treatment
by Zacks Equity Research
Allergan (AGN) secures an FDA approval for Botox Cosmetic product for its third indication of forehead line development.
The Zacks Analyst Blog Highlights: Pfizer, AT&T, BlackRock U.S. Bancorp and Walt Disney
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, AT&T, BlackRock U.S. Bancorp and Walt Disney
Quality Dividend ETFs for Turbulent Times
by Zacks Equity Research
Consider these 3 dividend ETFs for your portfolio to fight rising market uncertainty.
Agilent Boosts Market Share With FDA Nod to New Cancer Test
by Zacks Equity Research
Agilent Technologies' (A) recent FDA approval for a cancer diagnostic, PD-L1 IHC 28-8 pharmDx for UC and SCCHN patients will further expand its share in the growing cancer-diagnostic market.
Pharma Stock Roundup: J&J Drug Gets CRL, Label Expansion for Merck and BMY Drugs
by Arpita Dutt
Industry heavyweights like Johnson & Johnson (JNJ), Merck and Bristol-Myers were in the news related to regulatory updates.
Merck's Keytruda Gets FDA Nod for Advanced Gastric Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda received FDA approval for advanced gastric cancer, making it the tenth new indication approved for Keytruda.
Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval
by Zacks Equity Research
Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.
Dow 30 Stock Roundup: BA Wins $600M Air Force Contract, JPM Invests in Bill.com
by Swarup Gupta
The Dow mopped up gains over the week, buoyed by announcements from the Federal Reserve.
Cancer Space Update: Mixed Week for Pfizer, Roche Falters
by Zacks Equity Research
Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.
Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update
by Arpita Dutt
Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.
Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake
by Zacks Equity Research
Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.
Can Pfizer (PFE) Prove to be an Apt Value Investment?
by Zacks Equity Research
Let's find out if Pfizer, Inc. (PFE) stock is a good choice for value-oriented investors right now
Mylan Down 24% Year to Date: What's Troubling the Stock?
by Zacks Equity Research
Shares of Mylan N.V. (MYL) have declined 24.7% in the last six months compared to the industry's loss of 20%.
Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View
by Zacks Equity Research
Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.